← Eichor
Condition: Advanced Neuroendocrine Carcinomas Of The Digestive System Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Neuroendocrine Carcinomas Of The Digestive System

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S
Phase 1 · 1 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT07376707A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Phase 1 · 13 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT06839105Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Phase 2 · 2 location(s) · AC Camargo Cancer Center · NCT06472388Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres
Phase 1 · 5 location(s) · Novelty Nobility, Inc. · NCT06805825A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Phase 2 · 19 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT07061080IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.